Article
Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.
International journal of molecular sciences - 4 Oct 2022
Hattinger Claudia Maria, Casotti Chiara, Patrizio Maria Pia, Luppi Silvia, Fantoni Leonardo, Scotlandi Katia, Ibrahim Toni, Serra Massimo
Abstract excerpt
Cisplatin (CDDP) is a drug for high-grade osteosarcoma (HGOS) treatment. Several germline pharmacogenetic studies have revealed associations between single nucleotide polymorphisms (SNPs) and CDDP-based therapy response or CDDP-related toxicity in patients with HGOS. Whether these variants could play a biological role in HGOS cells has not been studied so far. The aim of this study was to explore 28 SNPs of 14...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
